Disease Landscape and Forecast 인사이트

The advent of Opdivo (Bristol Myers Squibb / Ono Pharmaceutical) and Keytruda (Merck & Co.) has revolutionized the treatment of gastroesophageal cancer, leading to substantial growth of this…

The small-cell lung cancer (SCLC) treatment landscape is dominated by chemotherapy and chemoradiotherapy. In the last 30 years, only two immunotherapies have been approved in this indication:…

Market outlookAlzheimer’s disease (AD) is a progressive and irreversible brain disorder that leads to a decline in cognitive abilities, affecting memory and causing patients’ quality of life to…

Immune checkpoint inhibitors have revolutionized the treatment landscape for bladder cancer and upper tract urothelial carcinoma (UTUC). Initially confined to advanced disease, the anti-PD-1…

Acute myeloid leukemia (AML) is associated with poor outcomes and low five-year overall survival rates. Although chemotherapy has been the mainstay AML treatment for a long time, the recent…

Heart failure (HF) manifests as impaired cardiac function and consequent failure to maintain sufficient blood flow throughout the body to meet its metabolic demands. Acute heart failure (AHF) and…

Approximately 80% of rare diseases have a genetic etiology. Gene therapies have the potential to transform the treatment of rare diseases and, in some cases, provide a functional cure. However,…

The type 2 diabetes (T2D) therapy market will expand through 2033, supported by polypharmacy and growing use of later-line therapies offering nonglycemic benefits. However, the loss of exclusivity…

Immunoglobulin A nephropathy (IgAN), or Berger’s disease, is an autoimmune disease that causes galactose-deficient IgA1 (Gd-IgA1) to accumulate in the kidney glomeruli, impairing their blood…

Myelofibrosis is a hematological malignancy characterized by disrupted blood cell production and bone marrow scarring. Symptoms include severe anemia, weakness, fatigue, and splenomegaly. The JAK…

The launch of several novel therapies, as well as multiple label expansions of existing drugs, will fuel significant growth of the NHL therapy market in China over the next 10 years. Rituximab (…

Clarivate Epidemiology’s coverage of the RSV vaccine comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany…